Drug Trial Radar · NCT05735951
Pharmacokinetic Parameters of Stiripentol in Renal Impaired Patients and Matching Controls With Normal Renal Function
Last checked: Nov 19, 2026Latest source record: Sep 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Jul 24, 2023
Primary completion
Nov 30, 2024
Study completion Nov 30, 2024
Sponsor
- Lead sponsor
- BiocodexIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether the pharmacokinetics (PK) of stiripentol and of its relevant metabolites would be altered in subjects with renal impairment compared with normal controls in order to assess the need of dose adjustment in the renal impaired population. This study will include subjects with mild, moderate and severe renal impairment.
Conditions
- Chronic Renal Insufficiency
Interventions
STIRIPENTOL oral administrationDrug
Oral administration of: * Days 1 and 2: 1000 mg of stiripentol (single dose at the end of breakfast), * Day 3 to Day 14: 1000 mg of stiripentol bis in die (BID) (approximately 12 hours apart, at the end of breakfast and at the end of dinner), * Day 15: 1000 mg of stiripentol (single dose at the end of breakfast).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration versus time curveTime frame: Steady state at Day15
- Peak Plasma ConcentrationTime frame: Steady state at Day15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mc Comac Medical
Sofia, Bulgaria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.